NCT07096999Recruiting
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 23 Jan 2025
- Primary completion date
- 23 Jan 2031
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT07096999
What you commit to
- Study type: Observational
- Planned participants: 60
- From 23 Jan 2025 to the primary completion date, 23 Jan 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Who the study is looking for
- \* 177Lu-617 PSMA treatment scheduled for mCRPC
- Clinically stable as determined by the nuclear medicine clinicians
- Male
- ≥ 18 years of age
- Willing and able to provide informed consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Of Michigan Comprehensive Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.